Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Symbool: 300357.SZ
SHZ
25.97
CNYMarktprijs vandaag
44.2441
Koers/Winst Verhouding
-6.3048
Koers/Winst Groei Verhouding
13.60B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1288.8 | 1135.7 | 1020.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 117.4 | 295.1 | 370.9 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 214.9 | 284.9 | 256.2 | |||||||||||||||
balance-sheet.row.inventory | 0 | 59 | 48.4 | 53.8 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 7.2 | 8.1 | 10.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 1569.9 | 1477.1 | 1341.5 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 704.8 | 444.6 | 301.6 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | -43.2 | -216.7 | -287.6 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 5 | 4.9 | 5.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 137.2 | 298.4 | 394.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 992.3 | 720.7 | 590.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 8 | 7.7 | 5.1 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 41.2 | 4 | 5.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 14.5 | 30.3 | 62.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 30.9 | 27.4 | 24.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 127.5 | 91.1 | 96.6 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 81.4 | 68 | 27.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 258.5 | 170.8 | 135.4 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 523.6 | 523.6 | 523.6 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 1262.6 | 1092.7 | 889.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 270.7 | 235.1 | 194.7 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 128.2 | 128.2 | 128.2 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2185.1 | 1979.6 | 1736.1 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 118.6 | 47.5 | 60.5 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 2303.7 | 2027.1 | 1796.6 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 74.2 | 78.4 | 83.3 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 62.4 | 16.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | 0 | -1108.9 | -824.4 | -642.2 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 295.5 | 335.7 | 326.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 38.5 | 26.1 | 25.1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0.5 | -1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | -0.5 | 1 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 47.4 | -47.2 | 11.5 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -30.9 | -34.6 | |||||||||||||||
cash-flows.row.inventory | 0 | -9.4 | 4.1 | -5.4 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | -20.9 | 52.5 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 56.8 | 0.5 | -1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0.7 | 45.7 | -2.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0.2 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -600.1 | -484.4 | -843.1 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 612.2 | 517.6 | 742.7 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 5.1 | 37.1 | 10.2 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -191.9 | -118.2 | -212.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -20 | -5.8 | -5.8 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -105.6 | -105.2 | -83.8 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 77.2 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -23.4 | -111 | -89.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 166.8 | 131.1 | 58.7 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 577.6 | 410.8 | 279.7 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 410.8 | 279.7 | 221 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 382.1 | 360.3 | 360.6 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 172.9 | 171.5 | 238.4 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 848.2 | 896 | 807.7 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 40.2 | 41.3 | 34.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 808 | 854.7 | 773.3 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 494.2 | 439.5 | 407.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 534.4 | 480.8 | 441.6 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 31 | 24.8 | 22.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 38.5 | 75.9 | 27.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 345 | 396.2 | 392.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 346 | 398.7 | 393 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 50.4 | 63 | 66.7 | |||||||||||||||
income-statement-row.row.net-income | 0 | 310.2 | 348.8 | 338 |
Vaak gestelde vragen
Wat is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) totale activa?
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) totale activa is 2562166715.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.953.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.360.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.392.
Wat is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) nettowinst (netto-inkomen)?
De nettowinst is 310184878.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 62443059.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 494184515.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.